GB2610070A - Coronavirus vaccine formulations - Google Patents

Coronavirus vaccine formulations Download PDF

Info

Publication number
GB2610070A
GB2610070A GB2212336.8A GB202212336A GB2610070A GB 2610070 A GB2610070 A GB 2610070A GB 202212336 A GB202212336 A GB 202212336A GB 2610070 A GB2610070 A GB 2610070A
Authority
GB
United Kingdom
Prior art keywords
glycoprotein
fraction
saponaria molina
quillaja saponaria
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2212336.8A
Other languages
English (en)
Other versions
GB202212336D0 (en
Inventor
Smith Gale
J Massare Michael
tian Jing-hui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of GB202212336D0 publication Critical patent/GB202212336D0/en
Publication of GB2610070A publication Critical patent/GB2610070A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GB2212336.8A 2020-01-27 2021-01-27 Coronavirus vaccine formulations Withdrawn GB2610070A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Publications (2)

Publication Number Publication Date
GB202212336D0 GB202212336D0 (en) 2022-10-12
GB2610070A true GB2610070A (en) 2023-02-22

Family

ID=77079351

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2212336.8A Withdrawn GB2610070A (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Country Status (14)

Country Link
US (1) US20230070886A1 (https=)
EP (1) EP4097123A4 (https=)
JP (2) JP7792339B2 (https=)
KR (1) KR20220141302A (https=)
CN (1) CN115720581A (https=)
AU (1) AU2021214064A1 (https=)
BR (1) BR112022014830A2 (https=)
CA (1) CA3165371A1 (https=)
GB (1) GB2610070A (https=)
IL (1) IL295142A (https=)
MX (1) MX2022009167A (https=)
TW (1) TW202142555A (https=)
WO (1) WO2021154812A1 (https=)
ZA (1) ZA202401922B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022235663A1 (en) * 2021-05-05 2022-11-10 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN116041448B (zh) * 2021-08-26 2025-05-13 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100017904A1 (en) * 2005-05-10 2010-01-21 Mark Scott Abad Genes and uses for plant improvement
US20150265698A1 (en) * 2008-12-09 2015-09-24 Novavax, Inc. Modified rsv f proteins and methods of their use
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102399854B1 (ko) * 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
EP4494650A3 (en) * 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100017904A1 (en) * 2005-05-10 2010-01-21 Mark Scott Abad Genes and uses for plant improvement
US20150265698A1 (en) * 2008-12-09 2015-09-24 Novavax, Inc. Modified rsv f proteins and methods of their use
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOLLIS et al. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion ut does not affect viron entry. Virology. 5 July 2006, Vol.350, No.2, pp 358-369; especially abstract; Fig 1 *
KLEINE-WEBER et al. Functional analysis of potential cleavage sites in the MERS coronavirus spoke protein, Scientific Reports. 09 November 2018, Vol. 8, No 1, article 16597 (pp1-11) especially abstract; Fig 1 *
TIAN et al. SARS-CoV-2, spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nature Communications. 14 January 2021, Vol. 12, No. 1, article 372 (pp1-14); entire document *

Also Published As

Publication number Publication date
CN115720581A (zh) 2023-02-28
BR112022014830A2 (pt) 2022-09-27
EP4097123A1 (en) 2022-12-07
IL295142A (en) 2022-09-01
TW202142555A (zh) 2021-11-16
JP2026026092A (ja) 2026-02-16
GB202212336D0 (en) 2022-10-12
ZA202401922B (en) 2025-04-30
MX2022009167A (es) 2022-08-17
JP7792339B2 (ja) 2025-12-25
KR20220141302A (ko) 2022-10-19
US20230070886A1 (en) 2023-03-09
AU2021214064A1 (en) 2022-08-18
WO2021154812A8 (en) 2022-02-24
EP4097123A4 (en) 2024-02-14
WO2021154812A1 (en) 2021-08-05
JP2023512648A (ja) 2023-03-28
CA3165371A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
GB2610070A (en) Coronavirus vaccine formulations
CN114404584B (zh) 一种新型冠状病毒mRNA疫苗及其制备方法和用途
JP2026026092A5 (https=)
US20140154280A1 (en) Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
EP1545625B1 (en) Flexible vaccine assembly and vaccine delivery platform
CA2305683A1 (en) Immunogenic peptides from the hpv e7 protein
JPWO2021050864A5 (https=)
WO2021233213A1 (zh) mRNA或mRNA组合物及其制备方法和应用
JP2004507231A5 (https=)
CA2293692A1 (en) Methods and reagents for vaccination which generate a cd8 t cell immune response
CA2461579A1 (en) Porcine adenovirus e1 region
JPWO2021154812A5 (https=)
JPWO2022203963A5 (https=)
WO2024041612A1 (zh) 一种正痘病毒属mRNA疫苗及其制备方法和用途
HK40088677A (en) Coronavirus vaccine formulations
EP1497412A2 (en) Adenovirus vectors for immunotherapy
EP3892296A1 (en) Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine
US11666649B2 (en) Vectors and vaccine cells for immunity against Zika virus
CN118576725B (zh) 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用
RU2023126867A (ru) Вакцинные составы против коронавируса
Liu et al. Silica-calcium phosphate nanoparticles delivering recombinant influenza hemagglutinin DNA can induce long-lasting T cell immune cross-protection in mice
WO2005091753A2 (en) Flexible vaccine assembly and vaccine delivery platform
JPWO2022235663A5 (https=)
KR20190123257A (ko) Sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
AU2017363967B2 (en) Viral vector constructs for expression of genetic adjuvants activating the CD40 and sting pathways

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088677

Country of ref document: HK

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)